Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.

Naunyn-Schmiedeberg's Archives of Pharmacology
Cynthia KwanPhilippe Huot

Abstract

Parkinson's disease (PD) psychosis afflicts over half of patients and poses a significant burden on quality of life. The aetiology of PD psychosis is multifactorial and likely arises from the complex interaction between dopamine replacement therapy and disease state. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset is a validated model to predict the efficacy of therapeutic compounds for treatment-related complications, including PD psychosis. In this model, psychosis-like behaviours (PLBs) encompass stereotypies that are idiosyncratic in nature and reproducible with each L-3,4-dihydroxyphenylanaline (L-DOPA) administration. In the present study, we sought to expand upon the existing repertoire of PLBs through the characterisation of novel stereotypical behaviours that appear dependent on the environment. We then discuss our findings in the context of clinical reports on stereotypical behaviours termed "punding" in subjects with PD, which consists of stereotypical repetitive and senseless behaviours. The poor understanding of the pathophysiology governing punding and consequent lack of effective therapies stand to benefit from enhanced characterisation of these stereotypical behaviours in a valid...Continue Reading

References

Feb 16, 1967·The New England Journal of Medicine·G C CotziasL M Schiffer
Apr 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·D LaplaneB Dubois
Oct 1, 1994·Progress in Neurobiology·R M Ridley
Sep 1, 1994·Biological Psychiatry·J H Friedman
Nov 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·R K PearceC D Marsden
Mar 10, 1998·Neuroscience and Biobehavioral Reviews·F Toates
Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·H H Fernandez, J H Friedman
Feb 13, 2002·Neurology·E VolleB Dubois
Mar 24, 2004·Parkinsonism & Related Disorders·Hideto MiwaTomoyoshi Kondo
Apr 13, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Valerie Voon
Apr 13, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Andrew H EvansAndrew J Lees
Apr 13, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Roger Kurlan
Nov 20, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Mariese A HelyRobert Trafficante
Jun 21, 2005·Parkinsonism & Related Disorders·Hideto Miwa, Tomoyoshi Kondo
Apr 26, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Alfonso FasanoAnna Rita Bentivoglio
Sep 9, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Naomi P VisanjiSusan H Fox
Oct 3, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Laura Silveira-MoriyamaAndrew J Lees
Jan 16, 2007·Arquivos de neuro-psiquiatria·Arthur KummerAntonio Lucio Teixeira
Jan 19, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Janis M MiyasakiValerie Voon
Oct 5, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Andrew J LawrenceBarbara J Sahakian
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezChristopher G Goetz
Mar 1, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Mariese A HelyJohn G L Morris
Apr 2, 2008·Drug and Alcohol Dependence·Alfonso FasanoFederico Tonioni
Nov 4, 2008·Clinical Neuropharmacology·Thomas S WingoMark Stacy
Sep 11, 2009·Journal of the Neurological Sciences·Gilles Fénelon, Guido Alves
Jan 20, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jaime Kulisevsky, Javier Pagonabarraga
Feb 23, 2010·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Susan H FoxJonathan M Brotchie
May 4, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Gilles FénelonLaurent Cleret de Langavant
May 22, 2010·Molecular Psychiatry·A Fasano, I Petrovic
Sep 16, 2010·Current Treatment Options in Neurology·Laura B Zahodne, Hubert H Fernandez
Nov 13, 2010·Journal of Neurology·A FasanoA R Bentivoglio
Jan 12, 2011·Neurobiology of Disease·E L LaneS B Dunnett
Jun 8, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Ashley H SpencerAndrea E Cavanna
Aug 2, 2011·Neurologic Clinics·Daniel E Rusyniak
Dec 15, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Alfonso Fasano, Andrew H Evans
Jan 18, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Pedro J Garcia-RuizIgnacio Mahillo Fernandez
Dec 11, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Isabelle Beaulieu-Boire, Anthony E Lang
Mar 6, 2016·Journal of the Neurological Sciences·Mauro PettorrusoAnna Rita Bentivoglio
Mar 11, 2018·The Journal of Pharmacology and Experimental Therapeutics·Nicolas VeyresPhilippe Huot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here